Upstream Bio (UPB) Stock Analysis

What Upstream Bio does

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Key metrics

ETFs linked to UPB

Broad-market and Healthcare sector ETFs an investor holding Upstream Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how UPB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Upstream Bio?

Upstream Bio trades under the ticker UPB on NASDAQ.

Which exchange is UPB listed on?

UPB is listed on NASDAQ.

What sector does Upstream Bio operate in?

Upstream Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze UPB in a portfolio?

PortView shows UPB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.